Clinical Trials Sponsored by Arog Pharmaceuticals LLC

Total 638 results

Arog Pharmaceuticals, Inc.

Completed

Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations

Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

United States
Arog Pharmaceuticals, Inc.

Completed

A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations

Acute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior Therapies

United States
Arog Pharmaceuticals, Inc.

Completed

Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification

Recurrent/Refractory Glioblastoma

United States
Arog Pharmaceuticals, Inc.

Completed

Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma

Esophagogastric Adenocarcinoma

United States
Arog Pharmaceuticals, Inc.

Available

Individual Patient Compassionate Use of Crenolanib

FLT3-ITD Mutation | FLT3/TKD Mutation | PDGFR-Alpha D842V | PDGFRA Gene Amplification

Italy
Arog Pharmaceuticals, Inc.

Completed

CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors

Advanced Solid Tumors

United States, Australia
Arog Pharmaceuticals, Inc.

Recruiting

Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

Newly Diagnosed FLT3 Mutated AML

United States
Arog Pharmaceuticals, Inc.

Recruiting

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

United States, Germany, Spain, Italy, France, Canada
Arog Pharmaceuticals, Inc.

Withdrawn

A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia

Relapsed/Refractory FLT3-mutated AML
Arog Pharmaceuticals, Inc.

Terminated

Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas

Glioma

United States
Arog Pharmaceuticals, Inc.

Completed

Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene

D842-related Mutant GIST

United States
Arog Pharmaceuticals, Inc.

Completed

Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients

Acute Myeloid Leukemia

United States
Arog Pharmaceuticals, Inc.

Completed

A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations

Newly Diagnosed AML With FLT3 Activating Mutations

United States
Arog Pharmaceuticals, Inc.

Completed

Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML

Relapsed/Refractory Acute Myeloid Leukemia (AML)

United States
Arog Pharmaceuticals, Inc.

Completed

Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients

Acute Myeloid Leukemia

United States
Arog Pharmaceuticals, Inc.

Withdrawn

A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.

Carcinoma, Non-Small-Cell Lung
Arog Pharmaceuticals, Inc.
Centre Leon Berard; Fox Chase Cancer Center

Unknown

Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST

GIST With D842V Mutated PDGFRA Gene

United States, France, Spain, Italy, Germany, Norway, Poland
St. Jude Children's Research Hospital
Ohio State University; Arog Pharmaceuticals, Inc.

Completed

Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies

Acute Myeloid Leukemia

United States
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS (OS440-3004)

Multiple Sclerosis | Spasticity, Muscle

Serbia, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Moldova, Republic of, Poland
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Multiple Sclerosis | Spasticity

United States, Russian Federation, Ukraine
Amneal Pharmaceuticals, LLC
Novum Pharmaceutical Research Services

Completed

Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg With Nasonex Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis

United States
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity

Multiple Sclerosis | Spasticity

United States, Russian Federation, Ukraine
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS (OS440-3005)

Multiple Sclerosis | Spasticity, Muscle

United States
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Withdrawn

To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS

Multiple Sclerosis | Sperm

United States
Amneal Pharmaceuticals, LLC
Symbio, LLC

Completed

Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg as an Analgesic for Short-Term Treatment in Female Subjects Suffering From Moderate-to-Severe Pain and Burning Upon Urination Associated With Uncomplicated Urinary Tract Infections (uUTI)

Uncomplicated Urinary Tract Infections

United States
Saptalis Pharmaceuticals LLC
bioRASI, LLC

Completed

A Bioequivalence Study With Clinical Endpoints to Evaluate the Safety and Therapeutic Equivalence of Permethrin Cream 5% & Elimite™ in Subjects With Scabies

Scabies

United States
Kind Pharmaceuticals LLC

Not yet recruiting

A Study of Safety and Efficiency of AND017 in Patients With Transfusion Dependent and Non-transfusion Dependent β-thalassemia

β -Thalassemia
Kind Pharmaceuticals LLC

Not yet recruiting

A Study of AND017 in Cancer Related Anemic Patients Receiving Chemotherapy

Chemotherapy Induced Anemia
Cali Pharmaceuticals LLC

Recruiting

Herniorrhaphy for Postoperative Pain

Hernia, Inguinal

United States
Hikma Pharmaceuticals LLC

Recruiting

Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia (CARCML)

Chronic Myeloid Leukemia

Egypt
Deciphera Pharmaceuticals LLC

Completed

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumor

United States
Hikma Pharmaceuticals LLC

Completed

Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate (Sclera® or Marovarex ®, Hikma) in Routine Medical Practice in the Treatment of Relapsing-Remitting Multiple Sclerosis in MENA Region

Relapsing Remitting Multiple Sclerosis

Algeria, Egypt, Jordan
Deciphera Pharmaceuticals LLC

Completed

A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumor

United States
Salarius Pharmaceuticals, LLC

Enrolling by invitation

A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

Ewing Sarcoma | Myxoid Liposarcoma | Desmoplastic Small Round Cell Tumor | Angiomatoid Fibrous Histiocytoma | Extraskeletal Myxoid Chondrosarcoma | Clear Cell Sarcoma | Myoepithelial Tumor | Sclerosing Epithelioid Fibrosarcoma | Low Grade Fibromyxoid Sarcoma

United States
Deciphera Pharmaceuticals LLC

Completed

Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (INVICTUS)

Gastrointestinal Stromal Tumors

United States, France, Finland, United Kingdom, Germany, Netherlands, Italy, Belgium, Spain, Canada, Australia, Poland, Singapore
Cali Pharmaceuticals LLC

Completed

Evaluate the Safety and Pharmacokinetic Profile of CPL-01 in the Management of Acute Postoperative Pain

Abdominoplasty

United States
Cubist Pharmaceuticals LLC

Completed

A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)

Clostridium Difficile Infection
Thetis Pharmaceuticals LLC

Completed

PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA

Hypertriglyceridemia | Diabetes Mellitus, Non-Insulin-Dependent

United States
Deciphera Pharmaceuticals LLC

Withdrawn

Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)

Gastrointestinal Stromal Tumors
Hikma Pharmaceuticals LLC

Completed

Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients

Inflammatory Bowel Diseases | Crohn Disease | Ulcerative Colitis | Fistulizing Crohn's Disease

Saudi Arabia
Curatek Pharmaceuticals, LLC

Completed

Multi-Center Study of New Medications to Treat Vaginal Infections (SMART GIVES)

Vaginal Infection

United States
Cubist Pharmaceuticals LLC

Completed

Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008) (ASPECT-NP)

Lung Diseases | Healthcare-Associated Pneumonia | Ventilator-Associated Pneumonia
Cubist Pharmaceuticals LLC

Completed

Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard Antibiotics

Gram-positive Bacterial Infections

United States
Cubist Pharmaceuticals LLC

Completed

Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia

Pneumonia, Bacterial
Cubist Pharmaceuticals LLC

Completed

Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae

Pneumonia, Bacterial
Cubist Pharmaceuticals LLC

Completed

Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics

Gram Positive Bacterial Infection

United States
Sephoris Pharmaceuticals LLC

Terminated

Clinical Trial of the Safety and Efficacy of SP160412 in the Temporary Relief of Mild to Moderate Sunburn

Sunburn

Mauritius
Cubist Pharmaceuticals LLC

Completed

Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010)

Proven or Suspected Gram-negative Bacterial Infection | Peri-operative Prophylaxis
Cubist Pharmaceuticals LLC

Completed

Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)

Skin Diseases, Infectious | Skin Diseases, Bacterial
Cubist Pharmaceuticals LLC

Completed

Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)

Clostridium Difficile Infection

3

Subscribe